New EORTC guidelines for the treatment of anaemia in patients with cancer: Implications for nursing practice

European Journal of Oncology Nursing

Volumn 10, Issue 3, 2006, Pages 177-186

  Foubert, Jan ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b Gezondheidszorg ^*  (Belgium)

Author keywords

Anaemia; Cancer; Darbepoetin alfa; Epoetin alfa; Epoetin beta; Erythropoietic stimulating proteins; Fatigue

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ALGORITHM; ANEMIA; ARTICLE; DECISION TREE; DIFFERENTIAL DIAGNOSIS; DOCUMENTATION; DRUG ADMINISTRATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; METABOLISM; NEOPLASM; NURSE ATTITUDE; NURSING ASSESSMENT; ONCOLOGY NURSING; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINE; STANDARD;

ALGORITHMS; ANEMIA; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; DOCUMENTATION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; FATIGUE; HEMOGLOBINS; HUMANS; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION; PATIENT SELECTION; PRACTICE GUIDELINES;

EID: 33746005989     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2005.08.003     Document Type: Article

References (31)

1. ® (darbepoetin alfa). Summary of Product Characteristics, updated 21 September 2004.
2. Bokemeyer C., and Foubert J. Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Seminars in Oncology 31 (2004) 4-11
3. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., Repetto L., and Soubeyran P. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer 40 (2004) 2201-2216
4. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology 34 3, Suppl. 2 (1997) 13-19
5. Cella D., Evans W., Wallace J., Kallich J., Blayney D., and Vadhan-Raj S. The relationships between FACT-Fatigue (FACT-F) scores and physical function in patients with chemotherapy-induced anemia treated with darbepoetin alfa. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22 July 15 Suppl (2004) 8062
6. Crawford J., Cella D., Cleeland C., Cremieux P.Y., Demetri G.D., Sarokhan B.J., Slavin M.B., and Glaspy J.A. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95 (2002) 888-895
7. Curt G.A., and Johnston P.G. Cancer fatigue: the way forward. Oncologist 8 Suppl. 1 (2003) 27-30
8. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., Johnson D.H., Miaskowski C., Scherr S.L., Portenoy R.K., and Vogelzang N.J. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5 (2000) 353-360
9. Eatock M.M., Dillon E., Corcoran B., O'Reilly M., Moriarty M., Furlong E., Daly P., Berger A., Keane E., and Johnston P. Cancer fatigue in Ireland: All Ireland Fatigue Coalition (AIFC) professional and interim patient surveys. Proceedings of the American Society of Clinical Oncology 22 (2003) abs 3073
10. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer 84 (2001) 3-10
11. Elliot S., Heatherington AC., and Foote M.A. Chapter 6: erythropoietic factors, clinical pharmacology and pharmacokinetics. In: Morstyn G., Foote M.A., and Lieschke G.J. (Eds). Cancer drug Discovery and Development. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics (2004), Humana Press Inc., Totowa, NJ 97-123
12. Foubert, J., 2005. Guidelines do impact clinical practice! Focus on Anaemia in Cancer 6, 13-16.
13. Gillespie T.W. Anemia in cancer: therapeutic implications and interventions. Cancer Nursing 26 (2003) 119-128
14. Gordon M.S. Managing anemia in the cancer patient: old problems, future solutions. Oncologist 7 (2002) 331-341
15. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 91 (1999) 1616-1634
16. Hébert-Croteau N., Brisson J., Latreille J., Rivard M., Abdeelaziz N., and Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. Journal of Clinical Oncology 22 (2004) 3685-3693
17. ® FS (epoetin alfa). Summary of Product Characteristics, November 2004.
18. Ludwig H., and Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Seminars in Oncology 25 Suppl 7 (1998) 35-38
19. Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., Kosmidis P., Krzakowski M., Nortier J., Olmi P., Schneider M., and Schrijvers D. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 40 (2004) 2293-2306
20. Meehan K., Tchekmedyian S., Ciesla G., Kallich J., Erder M.H., and Smith R. The burden of weekly epoetin alfa injections to patients and their caregivers. Proceedings of the American Society of Clinical Oncology 22 (2003) abs 2186
21. Michie S., and Johnston M. Changing clinical behaviour by making guidelines specific. British Medical Journal 7 (2004) 343-345
22. Miller M., and Kearney N. Institutional management of cancer-related fatigue: a comparison of clinical specialities. European Journal of Oncology Nursing 6 (2002) 45-53
23. Mock, V., Atkinson, A., Barsevick, A., Blackwell, S., Cella, D., Cimprich, B., Cleeland, C., Eisenberger, M.A., Escalante, C.P., Hinds, P., Jackson, V., Jacobsen, P.B., O'Connor, T., Piper, B.F., Rugo, H.S., Sabbatini, P., Stahl, C., Stewart, F.C., Wagner, L.I., 2004. NCCN Clinical Practice Guidelines in Oncology: cancel related fatigue, Version 1, 2004. Available at http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf.
24. National Institutes of Health, 2002. State-of-the-science panel on symptom management in cancer: pain, depression, and fatigue held July 15-17, 2002. Final statement October 26, 2002. Available at http://consensus.nih.gov/ta/022/022_statement.htm.
25. Ragaz J., Spinelli J.J., Villeneuve G., Ellison L., and Coldman A. Beneficial impact of evolving breast cancer tumor guidelines between 1979-2000 on breast cancer population mortality trends in the western world. The Canadian experience. Proceedings of the European Society of Medical Oncology 29 (2004) abs 2050
26. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., Djulbegovic B., Goode M.J., Jakubowski A.A., Lee S.J., Miller C.B., Rarick M.U., Regan D.H., Browman .P., and Gordon M.S. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 (2002) 2303-2320
27. ® (epoetin beta). Summary of Product Characteristics, updated March 2003.
28. Sabbatini, P., Cella, D., Cleeland, C., Coccia, P.F., Demetri, G.D., Djulbegovic, B. Garst, J.L., Gore, M., Kraut, E.H., Lin, W-C., Millenson, M., Mock, V., Rodgers, G., Joseph Rosenthal, J., 2004. NCCN Clinical Practice Guidelines in Oncology: cancer and treatment-related anemia, Version 2.2004. Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.
29. Silliman R.A. Crossing the quality chasm in breast cancer care. Journal of Clinical Oncology 22 (2004) 3654-3656
30. Spivak J.L., and Cazzola M. Current thinking and treatment practices in anaemia-an interactive poll. Medical Oncology 17 Suppl. 1 (2000) S32-S37
31. Stone P., Richardson A., Ream E., Smith A.G., Kerr D.J., and Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Annals of Oncology 11 (2000) 971-975